Michael A. Postow
Memorial Sloan Kettering Cancer Center · 34 works · 5,147 citations · h-index 16
Top works
- Immune Checkpoint Blockade in Cancer Therapy
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- Immune Modulation in Cancer with Antibodies
- Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1
- Opportunistic infections in patients treated with immunotherapy for cancer
- Ipilimumab in patients with melanoma and autoimmune disease
- Checkpoint blocking antibodies in cancer immunotherapy
- CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
- Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway
- A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma
- Targeting Immune Checkpoints
- Immune-priming of the Tumor Microenvironment by Radiotherapy
- Immune checkpoint modulation: Rational design of combination strategies
- Checkpoint Blockade for the Treatment of Advanced Melanoma
- Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
- The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime?
- Markers for Anti-cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Therapy in Melanoma
- A phase 2 trial of IO102-IO103 and nivolumab-relatlimab in previously untreated, unresectable melanoma.
- IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies
- Management and Outcomes of Clostridioides difficile Infection in Patients on Immune Checkpoint Inhibitors